SAN DIEGO, July 6, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of its follow-on offering of 5,633,009 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 5,633,009 shares of its common stock at a combined public offering price of $0.7101 per share (or pre-funded warrant) and accompanying warrant, priced at-the-market under applicable Nasdaq rules. The warrants will have an exercise price of $0.7101 per share, will be exercisable upon the date of stockholder approval, and will expire on the five-year anniversary from the date of stockholder approval.
Aethlon Medical, Inc.(AEMD)Earnings, Financials & Key Ratios
AEMD•NASDAQ
$0.73
Price updated Jul 7, 2026
AboutAethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.Show more
- Revenue$0
- EBITDA-$7M+22.6%
- Net Income-$7M+46.6%
- EPS (Diluted)-10.61+87.6%
- ROE-142.89%+41.9%
AEMD Price & Volume
Aethlon Medical, Inc. (AEMD) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Risks Future Capital Solvency
Investment Thesis • Updated 2026Q4
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Capital exhaustion and dilution
Key Thesis Takeaways
- Aethlon Medical remains a speculative, pre-revenue entity heavily dependent on external financing to sustain its Hemopurifier clinical development.
- The company's reliance on equity-based funding, evidenced by significant stock-based compensation and a $175.1 million accumulated deficit, creates substantial dilution risk for shareholders.
- Investors should monitor the company's ability to secure strategic partnerships, as the current $5.0 million cash position provides a limited runway against consistent quarterly operating losses.
Verdict Logic
the company's lack of commercial revenue and a $175.1 million accumulated deficit suggest that the current business model is unsustainable without further dilutive financing.
AEMD Growth Metrics
Aethlon Medical, Inc. (AEMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM46.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM78.84%
Return on Capital
10 Years-138.58%
5 Years-111.87%
3 Years-137.01%
Last Year-140.99%
AEMD Recent Earnings
Aethlon Medical, Inc. (AEMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q3 2026Latest
Jun 10, 2026Metric
Actual
Est
EPS
$4.08+288.4%
$2.17
Rev
—
—
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$2.45-21.9%
$2.01
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$3.74-120.0%
$1.70
Rev
—
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$8.50-25.0%
$6.80
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 10, 2026 | $4.08vs $2.17+288.4% | — |
| Q1 2026 | Feb 12, 2026 | $2.45vs $2.01-21.9% | — |
| Q4 2025 | Nov 12, 2025 | $3.74vs $1.70-120.0% | — |
| Q3 2025 | Aug 13, 2025 | $8.50vs $6.80-25.0% | — |
Based on last 12 quarters of dataView full earnings history →
Latest AEMD News
Recent stock market news and headlines for Aethlon Medical, Inc. (AEMD)
PRNewsWire·1 day ago
Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ RulesPRNewsWire·Jun 26, 2026
Aethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®Peer-reviewed study identifies altered extracellular vesicles in Long COVID and provides additional scientific rationale for evaluating the Hemopurifier® as a potential treatment SAN DIEGO, June 26, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced publication of new peer-reviewed research in the International Journal of Molecular Sciences demonstrating that patients with Long COVID exhibit significantly increased levels of mannosylated extracellular vesicles (EVs) that can be captured using the same Galanthus nivalis agglutinin (GNA) affinity resin incorporated into the Company's Hemopurifier®. The study, conducted in collaboration with investigators from the University of California, San Francisco (UCSF), provides what we believe is new evidence supporting extracellular vesicles as a potential therapeutic target in Long COVID and helps establish a translational framework for future studies evaluating whether the Hemopurifier can remove disease-associated EVs and their molecular cargo.
Newsfile Corp·Jun 26, 2026
From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola OutbreakVancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 26, 2026) - Investorideas.com, a leading investment platform for retail investors
Peers Comparison
Key metrics vs top competitors for Aethlon Medical, Inc. (AEMD)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.73 | $555.51K | -0.07 | — | — | -142.89% | — | |
| $2.98 | $327.88K | -0.31 | — | -227.72% | -25.53% | — | |
| $15.90 | $38.57M | -3.24 | -28.6% | -135.66% | -177.4% | — | |
| $6.97 | $574.02M | 10.25 | 8.33% | 5.85% | — | — | |
| $0.72 | $32.23M | -0.87 | 15.84% | -49.3% | -1344.47% | — | |
| $22.86 | $11.8B | -13.06 | 5.72% | -9.7% | -16.5% | — |
Compare AEMD vs Peers
Aethlon Medical, Inc. (AEMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AEMD SEC Filings & Documents
Aethlon Medical, Inc. (AEMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
Jun 10, 2026·SEC
Material company update
Jun 4, 2026·SEC
Material company update
Mar 17, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when AEMD posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AEMD Frequently Asked Questions
Aethlon Medical, Inc. (AEMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is AEMD profitable?
Aethlon Medical, Inc. (AEMD) reported a net loss of $7.2M for fiscal year 2026.
Dividend & Returns
What is AEMD's return on equity?
Aethlon Medical, Inc. (AEMD) has a return on equity (ROE) of -142.9%. Negative ROE indicates the company is unprofitable.
What is Aethlon Medical, Inc.'s free cash flow?
Aethlon Medical, Inc. (AEMD) had negative free cash flow of $7.00T in fiscal year 2026, likely due to heavy capital investments.